Dr. Irwin Goldstein, medical director of the sexual medicine program at Alvarado Hospital, presented an oral and poster presentation of the "Phase III Clinical Trial for Female Sexual Arousal Disorder (FSAD) with Femprox®" for the treatment of FSAD in pre- and post-menopausal women at the Sexual Medicine Society of Northern America conference in Las Vegas Nov. 10-13, 2011.
Femprox is an alprostadil-based topical cream intended for the treatment of FSAD. San Diego-based Apricus Biosciences, Inc. has completed nine clinical studies to date, including one, 98-patient Phase II study in the U.S. and a 400-patient Phase III study in China. Dr. Goldstein is a member of the company's Femprox Clinical Advisory Board.
It is the company's understanding that no product is currently approved for FSAD in the U.S., a persistent or recurring inability to attain, or maintain adequate sexual excitement, causing personal distress.
Femprox® exerts a local, relaxant effect on vulvar and clitoral blood vessels in women, leading to increased blood flow. The resultant increase in lubrication and sensory feedback is believed to produce a clinically significant increase in sexual arousal in women with FSAD.